Israeli medical device company developing Alpha DaRT, a radiation therapy using alpha particles to treat solid tumors.
Israeli medical device company developing Alpha DaRT, a radiation therapy using alpha particles to treat solid tumors.
No widely sold product yet, so it is funded by cash raised from investors and spends it on clinical trials and on building up production of its radioactive sources. Regulatory approvals in each country decide when sales can begin. It went public through a 2022 merger with a blank-cheque company.
In one line: An early-stage alpha-radiation cancer therapy company.
Moat: narrow (IP / patents). Patented alpha-particle radiation technology offers a novel localized cancer treatment approach.
Headquarters: Jerusalem, Israel · Founded: 2016 · Employees: 112
Size Alpha Tau Medical (DRTS) is a United States Health Care company (Medical Specialties) with a market value of $1.11B, the 2162nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $12.01 on 18 Nov 2026.
Performance Over six months the shares gained 7.4%, against -9.9% for the median peer and -2.2% for the United States market (cap-weighted) — 6th highest of 20 in its peer set.
Valuation It trades at 25.17× book value against a peer median of 3.08× (3rd most expensive of 21).
Price implies The share price implies a return on equity of about 216.8%; Alpha Tau Medical delivers -141.7%, so the price asks more than the business earns today.
Next results Next results expected around 24 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | $0 | -$1.23M | -$1.10M | -$1.07M | -$979,000 |
| EBITDA | n/a | -$41.1M | -$34.9M | -$34.6M | -$31.2M |
| Net income | -$92.6M | -$42.6M | -$31.8M | -$29.2M | -$33.8M |
| Free cash flow | n/a | -$32.8M | -$22.0M | -$24.4M | -$24.8M |
| Capital expenditure | n/a | $6.08M | $2.24M | $6.40M | $904,000 |
| Total debt | $15.2M | $13.7M | $12.5M | $13.3M | $5.19M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | ROE | Price / book | Implied ROE |
|---|---|---|---|---|---|---|
| Alpha Tau Medical DRTS | $1.11B | +7% | n/a | -142% | 25.17× | 216.8% |
| Siemens Healthineers SHL.DE | $53.7B | +27% | +1% | 12% | n/a | n/a |
| Elekta EKTA-B.ST | $2.35B | 0% | -7% | -4% | 3.16× | 21.4% |
| Accuray ARAY | n/a | -81% | n/a | n/a | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | DRTS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.2% | -4.7% | 7th lowest of 21 |
| 6-month return | +7.4% | -9.9% | 6th highest of 20 |
| Return on equity | -141.7% | 7.2% | 2nd lowest of 21 |
| Price / book | 25.17× | 3.08× | 3rd most expensive of 21 |
| ROE the price implies | 216.8% | 21.9% | most demanding of 20 |
| ROE delivered | -141.7% | 7.2% | 2nd lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | ROE | Price / book | Implied ROE | Delivered ROE |
|---|---|---|---|---|---|---|---|---|
| Alpha Tau Medical DRTS | United States | $1.11B | +7% | n/a | -142% | 25.17× | 216.8% | -141.7% |
| Alphatec ATEC | United States | $1.10B | -14% | +15% | -308% | 85.37× | n/a | -308.1% |
| Beijing Strong Biotechnologies 300406.SZ | China | $1.13B | -4% | -4% | 7% | 2.08× | 13.0% | 6.6% |
| Freenome FRNM | United States | $1.08B | n/a | n/a | 21% | 2.24× | 14.2% | 20.8% |
| CLASSYS 214150.KS | South Korea | $1.08B | -60% | +16% | 21% | 2.58× | 11.0% | 20.7% |
| Integra LifeSciences IART | United States | $1.08B | -10% | +1% | 1% | 1.01× | 11.6% | 1.2% |
| Shandong Weigao Orthopaedic Device 688161.SS | China | $1.14B | -29% | -6% | 6% | 1.81× | 13.6% | 5.8% |
| Mingyue Optical Lens 301101.SZ | China | $1.07B | -4% | +14% | 12% | 3.86× | 23.9% | 12.4% |
| Guangzhou Hexin Instrument 688622.SS | China | $1.06B | +21% | -29% | -27% | 25.84× | 200.6% | -27.4% |
| SI-BONE SIBN | United States | $1.06B | +59% | +14% | -8% | 5.74× | 33.2% | -7.7% |
| IRadimed IRMD | United States | $1.05B | -9% | +11% | 23% | 9.89× | 68.5% | 23.4% |
| Tandem Diabetes Care TNDM | United States | $1.19B | +13% | +7% | -37% | 8.80× | 91.5% | -36.7% |
| Castle Biosciences CSTL | United States | $1.03B | +67% | +10% | -5% | 2.15× | 18.2% | -4.9% |
| Eckert & Ziegler EUZ.DE | Germany | $1.03B | -2% | +4% | 21% | 3.30× | 30.1% | 21.1% |
| Beijing Wandong Medical Technology 600055.SS | China | $1.03B | -26% | -11% | -8% | 1.60× | 11.3% | -7.7% |
| Inno Laser Technology 301021.SZ | China | $1.03B | -33% | +17% | 8% | 6.36× | 86.7% | 7.8% |
| PHC 6523.T | Japan | $1.02B | +34% | +3% | 9% | 0.96× | 8.3% | 9.1% |
| Shenzhen Edge Medical 2675.HK | Hong Kong | $1.21B | -51% | +132% | -1% | 3.56× | 21.9% | -1.1% |
| Eyebright Medical Technology (Beijing) 688050.SS | China | $1.21B | -16% | +21% | 8% | 2.72× | 17.2% | 8.4% |
| Amoy Diagnostics 300685.SZ | China | $1.01B | -15% | +7% | 18% | 3.40× | 28.0% | 17.6% |
| Edan Instruments 300206.SZ | China | $1.00B | -19% | +14% | 16% | 2.86× | 25.6% | 16.5% |